Healthcare news, straight from the source. https://healthcarenews.work en-us Thu, 16 Apr 2026 00:37:29 +0000 https://healthcarenews.work/news/2026-04-13-stryker-signs-definitive-agreement-acquire-amplitude-vascular-systems/ https://healthcarenews.work/news/2026-04-13-stryker-signs-definitive-agreement-acquire-amplitude-vascular-systems/ Mon, 13 Apr 2026 00:00:00 +0000 Healthcare News Context Stryker has signed a definitive agreement to acquire Amplitude Vascular Systems, a privately held medical technology company developing a next-generation intravascular lithotripsy platform designed to treat calcified peripheral arterial disease. Financial terms of the deal were not disclosed. The acquisition strengthens Stryker’s Peripheral Vascular portfolio by adding revascularization technology. Once the product receives clearance for use in applicable markets, it will complement Stryker’s existing peripheral vascular offerings and support the company’s strategy to expand its presence in arterial disease treatment.... Acquisition Peripheral Vascular Medical Devices Corporate Development Stryker https://healthcarenews.work/news/2026-04-13-medtronic-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2026/ https://healthcarenews.work/news/2026-04-13-medtronic-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2026/ Mon, 13 Apr 2026 00:00:00 +0000 Healthcare News Context Medtronic has announced it will report financial results for its fourth quarter and full fiscal year 2026 on Wednesday, June 3, 2026. The fiscal year ends on Friday, April 24, 2026. A news release with summary financial information will be distributed at 5:45 a.m. Central Time, followed by a video webcast discussing results at 6:45 a.m. CT. The webcast will be accessible at investorrelations.medtronic.com, with a replay and transcript of prepared remarks available within 24 hours. Medtronic, which trades on... Corporate Financial Results Earnings Announcement Investor Relations Medtronic https://healthcarenews.work/news/2026-04-13-dupixent-approved-eu-chronic-spontaneous-urticaria-young-children/ https://healthcarenews.work/news/2026-04-13-dupixent-approved-eu-chronic-spontaneous-urticaria-young-children/ Mon, 13 Apr 2026 00:00:00 +0000 Healthcare News Context The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years who have not responded adequately to antihistamines and are naive to anti-IgE therapy. The approval makes Dupixent the first targeted medicine in the EU indicated for young children with this condition. The decision builds on data from the LIBERTY-CUPID clinical program, including adult Phase 3 studies and the CUPIDKids pediatric Phase 3 study. Dupixent significantly reduced urticaria activity compared with... Regulatory Approval Immunology Pediatrics European Commission Sanofi https://healthcarenews.work/news/2026-04-09-novartis-announces-expansion-community-health-programs-close-gaps-heart-disease-and-cancer-care/ https://healthcarenews.work/news/2026-04-09-novartis-announces-expansion-community-health-programs-close-gaps-heart-disease-and-cancer-care/ Thu, 09 Apr 2026 00:00:00 +0000 Healthcare News Context Novartis has announced plans to expand its community health initiatives from 11 to over 30 countries by 2030, targeting underserved populations with heart disease and cancer. The expansion encompasses three distinct program types designed to close access gaps in diagnosis and treatment. The company is launching Inclusive Health Accelerators across five U.S. cities – New York, Los Angeles, Detroit, Houston, and Baltimore – focused on improving access to breast and prostate cancer care through awareness, screening, and referral facilitation. Separately,... Social Commitment Reimagine Medicine Innovation Cancer Heart Disease Novartis https://healthcarenews.work/news/2026-04-09-new-survey-finds-most-americans-believe-chronic-diseases-are-preventable/ https://healthcarenews.work/news/2026-04-09-new-survey-finds-most-americans-believe-chronic-diseases-are-preventable/ Thu, 09 Apr 2026 00:00:00 +0000 Healthcare News Context A new survey commissioned by Abbott and conducted by Kantar among 4,000 U.S. adults has uncovered a significant disconnect between what Americans believe about chronic disease prevention and how confident they feel managing their own health. While 74% of respondents said chronic diseases are preventable, only 25% reported feeling confident in their ability to care for their health. The findings paint a picture of a population overwhelmed by the complexity and cost of healthcare. Sixty-five percent said they had delayed... Chronic Disease Health Survey Consumer Health Nutrition Disease Prevention Abbott https://healthcarenews.work/news/2026-04-07-lunsekimig-phase2-asthma-crsnwp/ https://healthcarenews.work/news/2026-04-07-lunsekimig-phase2-asthma-crsnwp/ Tue, 07 Apr 2026 00:00:00 +0000 Healthcare News Context Sanofi has announced positive Phase 2 results for lunsekimig, a bispecific antibody designed to simultaneously block TSLP and IL-13, in two respiratory studies. The AIRCULES Phase 2b study met its primary and key secondary endpoints in moderate-to-severe asthma, demonstrating statistically significant reductions in exacerbations and improvements in lung function. The DUET Phase 2a study also met primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, showing improvements in nasal polyp scores, nasal congestion, and CT imaging. However, an... Clinical Trial Results Immunology Respiratory Phase 2 Sanofi https://healthcarenews.work/news/2026-03-31-rezurock-approved-eu-chronic-graft-vs-host-disease/ https://healthcarenews.work/news/2026-03-31-rezurock-approved-eu-chronic-graft-vs-host-disease/ Tue, 31 Mar 2026 00:00:00 +0000 Healthcare News Context The European Commission has granted conditional marketing authorization for Sanofi’s Rezurock (belumosudil), a selective ROCK2 inhibitor, to treat chronic graft-versus-host disease in patients aged 12 and older weighing at least 40 kg. The approval applies when other treatments offer limited benefit or are unsuitable. The authorization is based on data from the ROCKstar Phase 2 clinical trial, which demonstrated a 74% response rate. As a condition of the authorization, Sanofi must complete a confirmatory randomized controlled study. Professor Mohamad Mohty... Regulatory Approval Oncology Rare Disease European Commission Sanofi https://healthcarenews.work/news/2026-03-30-abbott-expands-access-to-precision-oncology-portfolio-through-integration-with-flatiron-oncoemr/ https://healthcarenews.work/news/2026-03-30-abbott-expands-access-to-precision-oncology-portfolio-through-integration-with-flatiron-oncoemr/ Mon, 30 Mar 2026 00:00:00 +0000 Healthcare News Context Abbott and Flatiron Health have announced the integration of Abbott’s Precision Oncology test portfolio into OncoEMR, Flatiron’s cloud-based electronic medical record platform. The integration enables oncology providers to digitally order and receive results for Abbott tests – including Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard – directly within their existing clinical workflow. The move expands access across Flatiron’s network of more than 1,600 community cancer care centers serving 4,700 providers. Quincy Weatherspoon, VP and GM of Point of... Precision Oncology Healthcare Technology Electronic Medical Records Cancer Diagnostics Medical Devices Abbott https://healthcarenews.work/news/2026-03-29-novartis-igan-data-new-england-journal-medicine-show-fabhalta-slowed-kidney-function-decline-493/ https://healthcarenews.work/news/2026-03-29-novartis-igan-data-new-england-journal-medicine-show-fabhalta-slowed-kidney-function-decline-493/ Sun, 29 Mar 2026 00:00:00 +0000 Healthcare News Context Final two-year results from the Phase III APPLAUSE-IgAN study show that Novartis’s Fabhalta (iptacopan) slowed the decline of kidney function by 49.3% compared to placebo in patients with IgA nephropathy, according to data published in the New England Journal of Medicine. The drug also reduced composite kidney failure events by 43% and helped 40.7% of patients achieve sustained proteinuria reduction to below 1 g/g, compared to 23.7% on placebo. The safety profile remained consistent with prior analyses, with mild-to-moderate infections,... Reimagine Medicine Rare Diseases Clinical Trials Kidney Disease Nephrology Novartis https://healthcarenews.work/news/2026-03-28-amlitelimab-phase3-atopic-dermatitis-aad/ https://healthcarenews.work/news/2026-03-28-amlitelimab-phase3-atopic-dermatitis-aad/ Sat, 28 Mar 2026 00:00:00 +0000 Healthcare News Context Sanofi has reported positive Phase 3 trial results for amlitelimab, a monoclonal antibody targeting OX40-ligand, in treating moderate-to-severe atopic dermatitis. The data were presented in a late-breaking session at the American Academy of Dermatology Annual Meeting in Denver. Three studies – COAST 1, COAST 2, and SHORE – demonstrated progressive efficacy improvements with both monthly and quarterly dosing schedules compared to placebo in patients aged 12 and older. Amlitelimab showed effectiveness both as monotherapy and in combination with topical treatments.... Clinical Trial Results Dermatology Immunology Phase 3 Conference Presentation Sanofi https://healthcarenews.work/news/2026-03-27-sarclisa-subcutaneous-chmp-multiple-myeloma/ https://healthcarenews.work/news/2026-03-27-sarclisa-subcutaneous-chmp-multiple-myeloma/ Fri, 27 Mar 2026 00:00:00 +0000 Healthcare News Context The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of a subcutaneous formulation of Sanofi’s Sarclisa (isatuximab) for treating multiple myeloma across all currently approved indications for the intravenous version. If approved, Sarclisa would become the first anticancer treatment available through both an on-body injector and manual injection, and the only anti-CD38 monoclonal antibody in multiple myeloma to offer both delivery methods. The recommendation is based on positive results from the Phase 3 IRAKLIA study... Regulatory Approval Oncology Multiple Myeloma CHMP Sanofi https://healthcarenews.work/news/2026-03-27-novartis-agrees-acquire-excellergy-inc-building-allergy-leadership-next-generation-anti-ige-innovation/ https://healthcarenews.work/news/2026-03-27-novartis-agrees-acquire-excellergy-inc-building-allergy-leadership-next-generation-anti-ige-innovation/ Fri, 27 Mar 2026 00:00:00 +0000 Healthcare News Context Novartis has agreed to acquire Excellergy, Inc., a private biotech developing next-generation anti-IgE therapies, for up to $2 billion in upfront and milestone payments. The deal’s lead asset, Exl-111, is a half-life extended, high-affinity anti-IgE antibody currently in Phase 1 development. Fiona Marshall, President of Biomedical Research at Novartis, said Exl-111 “is designed to go beyond conventional anti-IgE therapy, with potential to deliver faster and deeper suppression of IgE signaling.” Unlike conventional approaches, the antibody dissociates receptor-bound IgE to drive... Innovation Reimagine Medicine Acquisition Immunology Allergy Novartis https://healthcarenews.work/news/2026-03-27-medtronic-receives-fda-clearance-for-stealth-axis-surgical-system-for-cranial-and-ent-procedures/ https://healthcarenews.work/news/2026-03-27-medtronic-receives-fda-clearance-for-stealth-axis-surgical-system-for-cranial-and-ent-procedures/ Fri, 27 Mar 2026 00:00:00 +0000 Healthcare News Context Medtronic has received FDA clearance for the Stealth AXiS surgical system for use in cranial and ear, nose, and throat procedures, expanding the platform beyond its initial spine surgery clearance granted in February. The system combines surgical planning, navigation, and robotics capabilities in a unified platform powered by AI-enabled architecture. Key features include automatic tractography for generating patient-specific brain maps and visualizing critical neural pathways, along with integration of intraoperative ultrasound through GE HealthCare’s bkActiv system for real-time imaging. For... Neuroscience Portfolio Surgical Robotics Medical Devices FDA Clearance Cranial Surgery Medtronic https://healthcarenews.work/news/2026-03-26-uhc-introduces-ai-companion-empowering-people-with-simpler-navigation-personal-experience/ https://healthcarenews.work/news/2026-03-26-uhc-introduces-ai-companion-empowering-people-with-simpler-navigation-personal-experience/ Thu, 26 Mar 2026 00:00:00 +0000 Healthcare News Context UnitedHealthcare has launched Avery, a generative AI companion designed to simplify healthcare navigation for members through the UnitedHealthcare app and myuhc.com. The tool is currently available to 6.5 million commercial members and 160,000 Medicare Advantage participants, with plans to expand to 20.5 million total members by year-end. Avery handles a range of tasks including coverage details, appointment scheduling, cost estimates, rewards programs, provider searches, and claims status. The system can schedule appointments by calling primary care providers directly and transfers... Artificial Intelligence Technology Member Experience Healthcare Navigation UnitedHealth Group https://healthcarenews.work/news/2026-03-26-abbott-hosts-conference-call-for-first-quarter-earnings/ https://healthcarenews.work/news/2026-03-26-abbott-hosts-conference-call-for-first-quarter-earnings/ Thu, 26 Mar 2026 00:00:00 +0000 Healthcare News Context Abbott announced it will release first-quarter 2026 financial results on Thursday, April 16, before the market opens. A live webcast of the earnings conference call will follow at 8 a.m. Central time, accessible through Abbott’s Investor Relations website at abbottinvestor.com, with an archived version available later that day. Abbott, which employs approximately 122,000 people and serves patients in more than 160 countries, operates across diagnostics, medical devices, nutritionals, and branded generic medicines. The upcoming earnings report will be closely watched... Earnings Investor Relations Financial Results Conference Call Abbott https://healthcarenews.work/news/2026-03-24-q1-2026-aide-memoire-availability/ https://healthcarenews.work/news/2026-03-24-q1-2026-aide-memoire-availability/ Tue, 24 Mar 2026 00:00:00 +0000 Healthcare News Context Sanofi has made its Q1 2026 aide-memoire available on the company’s Investors webpage. The quarterly document supports financial modeling by covering non-comparable items, foreign currency impact, and share count information ahead of the full first-quarter results, which will be published on April 23, 2026. Sanofi is listed on EURONEXT under the ticker SAN and on NASDAQ under the ticker SNY. The aide-memoire provides analysts and investors with supplementary financial documentation to prepare their models in advance of the full earnings... Investor Relations Financial Reporting Q1 2026 Sanofi https://healthcarenews.work/news/2026-03-24-medtronic-and-merit-medical-systems-enter-into-agreement-to-offer-new-fda-cleared-viaverte-system/ https://healthcarenews.work/news/2026-03-24-medtronic-and-merit-medical-systems-enter-into-agreement-to-offer-new-fda-cleared-viaverte-system/ Tue, 24 Mar 2026 00:00:00 +0000 Healthcare News Context Medtronic has entered a distribution agreement with Merit Medical Systems to offer the FDA-cleared ViaVerte system, described as the first and only basivertebral nerve ablation system with a physician-controlled steerable mechanism for precise nerve targeting. The minimally invasive, implant-free procedure addresses chronic lower back pain caused by damaged vertebral endplates and will be available later in 2026. The agreement expands Medtronic’s pain interventions portfolio, which already includes spinal cord stimulation, vertebral augmentation, nerve ablation, bone tumor ablation, and targeted drug... Neuroscience Portfolio Medical Devices Pain Management Minimally Invasive Procedures FDA Clearance Medtronic https://healthcarenews.work/news/2026-03-24-dupixent-approved-japan-bullous-pemphigoid/ https://healthcarenews.work/news/2026-03-24-dupixent-approved-japan-bullous-pemphigoid/ Tue, 24 Mar 2026 00:00:00 +0000 Healthcare News Context Japan’s Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for treating adults with moderate-to-severe bullous pemphigoid, marking the seventh indication for the drug in Japan. The approval is based on the Phase 2/3 LIBERTY-BP-ADEPT trial, which showed more than four times as many patients on Dupixent achieved sustained disease remission compared to placebo at week 36, with rates of 18% versus 4%. Bullous pemphigoid is a chronic, relapsing skin condition characterized by intense itching, painful blisters, and lesions... Regulatory Approval Immunology Dermatology Japan Sanofi https://healthcarenews.work/news/2026-03-23-novartis-presents-new-data-early-symptom-relief-and-long-term-control-complex-skin-diseases-aad-2026/ https://healthcarenews.work/news/2026-03-23-novartis-presents-new-data-early-symptom-relief-and-long-term-control-complex-skin-diseases-aad-2026/ Mon, 23 Mar 2026 00:00:00 +0000 Healthcare News Context Novartis is presenting clinical findings from more than 20 abstracts at the American Academy of Dermatology Annual Meeting, highlighting advances across its immunology portfolio in complex skin diseases. Key presentations include new Rhapsido (remibrutinib) data demonstrating changes in daily itch and hives severity scores at week one in patients with chronic spontaneous urticaria. The company is also presenting Cosentyx (secukinumab) data comparing safety and flare prevention versus bimekizumab in hidradenitis suppurativa, along with four- and five-year efficacy data from pivotal... Reimagine Medicine Innovation Clinical Trials Chronic Illness Dermatology Novartis https://healthcarenews.work/news/2026-03-23-medtronic-omniasecure-defibrillation-lead-first-lead-fda-approval-conduction-system-pacing/ https://healthcarenews.work/news/2026-03-23-medtronic-omniasecure-defibrillation-lead-first-lead-fda-approval-conduction-system-pacing/ Mon, 23 Mar 2026 00:00:00 +0000 Healthcare News Context The FDA has approved an expanded indication for Medtronic’s OmniaSecure defibrillation lead, making it the first defibrillation lead cleared for placement in the left bundle branch area for conduction system pacing. The lead can now support left bundle branch optimized cardiac resynchronization therapy, combining conduction system pacing with left-ventricular pacing to improve patient outcomes. At just 4.7 French (1.66 mm), the OmniaSecure is the smallest diameter defibrillation lead on the market. It connects to implantable cardioverter-defibrillators or cardiac resynchronization therapy... Cardiac Rhythm Management Medical Devices FDA Approval Defibrillation Technology Conduction System Pacing Medtronic https://healthcarenews.work/news/2026-03-23-abbott-completes-acquisition-of-exact-sciences/ https://healthcarenews.work/news/2026-03-23-abbott-completes-acquisition-of-exact-sciences/ Mon, 23 Mar 2026 00:00:00 +0000 Healthcare News Context Abbott has completed its acquisition of Exact Sciences, positioning the healthcare giant as a significant player in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments. Exact Sciences is now a wholly owned Abbott subsidiary. Chairman and CEO Robert B. Ford said the move will “expand access to important tools for early cancer detection and personalized treatments.” The acquired portfolio includes Cologuard for colorectal cancer screening, Oncotype DX for breast cancer treatment guidance, Oncodetect for molecular residual... Acquisition Cancer Screening Precision Oncology Diagnostics Corporate Strategy Abbott https://healthcarenews.work/news/2026-03-20-novartis-agrees-acquire-pan-mutant-selective-pi3ka-inhibitor-strengthening-its-breast-cancer-pipeline/ https://healthcarenews.work/news/2026-03-20-novartis-agrees-acquire-pan-mutant-selective-pi3ka-inhibitor-strengthening-its-breast-cancer-pipeline/ Fri, 20 Mar 2026 00:00:00 +0000 Healthcare News Context Novartis has agreed to acquire SNV4818, a pan-mutant-selective PI3Ka inhibitor in Phase 1/2 development, from Synnovation Therapeutics for $2 billion upfront plus up to $1 billion in milestone payments. The compound targets HR+/HER2- breast cancer and other solid tumors, with approximately 40% of HR+/HER2- breast cancer patients carrying PIK3CA mutations associated with worse prognosis. What distinguishes SNV4818 from existing PI3Ka inhibitors is its selectivity: the compound targets mutated PI3Ka while sparing the wild-type form found in healthy cells, potentially improving... Oncology Medical Innovations Cancer Reimagine Medicine Acquisition Novartis https://healthcarenews.work/news/2026-03-20-abbott-acquisition-of-exact-sciences-set-to-close-on-march-23-2026/ https://healthcarenews.work/news/2026-03-20-abbott-acquisition-of-exact-sciences-set-to-close-on-march-23-2026/ Fri, 20 Mar 2026 00:00:00 +0000 Healthcare News Context Abbott confirmed that its acquisition of Exact Sciences is on track to close on March 23, 2026, with the cancer diagnostics company set to become a wholly owned subsidiary upon completion of the transaction. The deal represents a major strategic expansion for Abbott into the cancer screening and precision oncology diagnostics market. The acquisition brings together Abbott’s global healthcare infrastructure with Exact Sciences’ portfolio of cancer detection and monitoring tests, including Cologuard for colorectal cancer screening and Oncotype DX for... Acquisition Cancer Screening Precision Oncology Diagnostics Corporate Strategy Abbott https://healthcarenews.work/news/2026-03-18-venglustat-breakthrough-therapy-gaucher-disease-type3/ https://healthcarenews.work/news/2026-03-18-venglustat-breakthrough-therapy-gaucher-disease-type3/ Wed, 18 Mar 2026 00:00:00 +0000 Healthcare News Context The FDA has granted Breakthrough Therapy designation to Sanofi’s venglustat, an investigational oral glucosylceramide synthase inhibitor, for treating neurological manifestations of type 3 Gaucher disease. The designation is based on Phase 3 LEAP2MONO study data showing statistically significant improvements in neurological symptoms compared with imiglucerase enzyme replacement therapy. Type 3 Gaucher disease is a rare inherited lysosomal storage disorder caused by glucocerebrosidase enzyme deficiency, leading to glycosphingolipid accumulation. Symptoms include ataxia, cognitive decline, liver and spleen enlargement, anemia, and bone... Regulatory Designation Rare Disease Neurology FDA Sanofi https://healthcarenews.work/news/2026-03-17-uhg-announces-q1-earnings-release-date/ https://healthcarenews.work/news/2026-03-17-uhg-announces-q1-earnings-release-date/ Tue, 17 Mar 2026 00:00:00 +0000 Healthcare News Context UnitedHealth Group will release first-quarter 2026 financial results on Tuesday, April 21, 2026, before market opens. The company will host a teleconference at 8:00 a.m. Eastern with analysts and investors, with the webcast available on the Investor Relations page at unitedhealthgroup.com. A replay will be accessible through May 5, 2026. UnitedHealth Group operates through two complementary divisions: Optum, which delivers technology-enabled care solutions, and UnitedHealthcare, which provides health benefits and coverage options. The company trades on the NYSE under the... Investor Relations Earnings Financial Results UnitedHealth Group https://healthcarenews.work/news/2026-03-13-novartis-cosentyx-receives-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-suppurativa/ https://healthcarenews.work/news/2026-03-13-novartis-cosentyx-receives-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-suppurativa/ Fri, 13 Mar 2026 00:00:00 +0000 Healthcare News Context The FDA has approved Novartis’s Cosentyx (secukinumab) for pediatric patients aged 12 and older with moderate to severe hidradenitis suppurativa, making it the only IL-17A inhibitor approved for this population. The approval marks the fourth pediatric indication for the drug, which has treated over 1.8 million patients since its 2015 launch. Hidradenitis suppurativa is a chronic, systemic inflammatory skin disease affecting approximately 1 in 100 people worldwide, often beginning during adolescence. The condition causes recurring boil-like lesions that rupture into... Reimagine Medicine Innovation Chronic Illness FDA Approval Dermatology Novartis https://healthcarenews.work/news/2026-03-12-landmark-study-shows-libre-technology-helps-people-with-type-2-diabetes-on-basal-insulin-improve-glucose-management/ https://healthcarenews.work/news/2026-03-12-landmark-study-shows-libre-technology-helps-people-with-type-2-diabetes-on-basal-insulin-improve-glucose-management/ Thu, 12 Mar 2026 00:00:00 +0000 Healthcare News Context Results from the FreeDM2 randomized controlled trial demonstrate that Abbott’s FreeStyle Libre continuous glucose monitoring technology significantly improves glucose outcomes compared to traditional fingerstick testing in people with Type 2 diabetes on basal insulin. The study, involving 303 participants across 24 clinical sites in the United Kingdom, found that CGM users achieved a 0.6% greater reduction in HbA1c and spent approximately 2.5 additional hours daily within healthy glucose ranges at the four-month mark. A complementary Italian study of 88 adults... Diabetes Continuous Glucose Monitoring Clinical Study FreeStyle Libre Type 2 Diabetes Abbott https://healthcarenews.work/news/2026-03-11-abbott-and-real-madrid-launch-nationwide-effort-to-build-the-next-abbott-dream-team/ https://healthcarenews.work/news/2026-03-11-abbott-and-real-madrid-launch-nationwide-effort-to-build-the-next-abbott-dream-team/ Wed, 11 Mar 2026 00:00:00 +0000 Healthcare News Context Abbott and Real Madrid have launched the second edition of the Abbott Dream Team, a nationwide youth development program combining soccer training with health and nutrition education for young athletes aged 18 to 19. The initiative will hold free selection events in six U.S. cities between May and June 2026, including Miami, Washington D.C., Houston, Kansas City, Los Angeles, and Chicago. Sixteen participants, both male and female, will be selected to receive an all-expenses-paid trip to Madrid for training at... Youth Health Sports Partnership Soccer Nutrition Community Health Abbott https://healthcarenews.work/news/2026-03-11-a-message-to-our-customers-03-2026/ https://healthcarenews.work/news/2026-03-11-a-message-to-our-customers-03-2026/ Wed, 11 Mar 2026 00:00:00 +0000 Healthcare News Context Stryker Corporation experienced a cyberattack on March 11, 2026, affecting its Microsoft environment, but the company confirmed the incident was contained to its own internal systems with no malware or ransomware detected. All connected products, including the Mako surgical system, Vocera communication devices, LIFEPAK equipment, and navigation systems, were confirmed safe to use throughout the incident. Manufacturing and ordering systems were disrupted but restoration progressed rapidly. By April 1, 2026, operations returned to full status with production moving toward peak... Cybersecurity Network Disruption Customer Updates Operations Stryker https://healthcarenews.work/news/2026-03-10-medtronic-to-acquire-scientia-vascular-marrying-access-and-therapeutic-portfolios-for-neurovascular-care/ https://healthcarenews.work/news/2026-03-10-medtronic-to-acquire-scientia-vascular-marrying-access-and-therapeutic-portfolios-for-neurovascular-care/ Tue, 10 Mar 2026 00:00:00 +0000 Healthcare News Context Medtronic has announced a definitive agreement to acquire Scientia Vascular, a Salt Lake City-based medical device company, for $550 million plus undisclosed earn-out and milestone payments. The deal brings Scientia’s guidewire and catheter access products into Medtronic’s existing neurovascular suite, strengthening procedural workflow support for treating complex neurovascular conditions including stroke. Scientia, which employs approximately 310 people, has developed an access platform designed to navigate the complexity of cerebral vasculature with improved efficiency. Stroke affects 12 million people globally each... Neurovascular Portfolio Neuroscience Medical Device Acquisition Stroke Treatment Healthcare Innovation Medtronic https://healthcarenews.work/news/2026-03-05-board-christel-heydemann-independent-director/ https://healthcarenews.work/news/2026-03-05-board-christel-heydemann-independent-director/ Thu, 05 Mar 2026 00:00:00 +0000 Healthcare News Context Sanofi’s Board of Directors has proposed appointing Christel Heydemann as an independent director at the Annual General Meeting scheduled for April 29, 2026. The board also proposed renewing the mandates of existing directors Christophe Babule and Jean-Paul Kress. Patrick Kron, who served as independent director and chair of the Nomination, Governance and CSR Committee, will step down at the end of his current term. Heydemann currently serves as CEO of Orange Group and previously held leadership roles at Schneider Electric... Corporate Governance Board of Directors Leadership Sanofi https://healthcarenews.work/news/2026-03-04-filing-document-enregistrement-universel-annual-financial-report/ https://healthcarenews.work/news/2026-03-04-filing-document-enregistrement-universel-annual-financial-report/ Wed, 04 Mar 2026 00:00:00 +0000 Healthcare News Context Sanofi has filed an amendment to its Document d’Enregistrement Universel with France’s market authority, the Autorite des marches financiers. The submission includes additions to the report on corporate governance established in accordance with French law. The updated document is available on Sanofi’s investor website and the AMF website. Sanofi is listed on EURONEXT under the ticker SAN and on NASDAQ under the ticker SNY. Financial Reporting Regulatory Filing Investor Relations Sanofi https://healthcarenews.work/news/2026-03-03-stryker-showcases-continued-innovation-across-orthopaedics-at-aaos-2026-annual-meeting/ https://healthcarenews.work/news/2026-03-03-stryker-showcases-continued-innovation-across-orthopaedics-at-aaos-2026-annual-meeting/ Tue, 03 Mar 2026 00:00:00 +0000 Healthcare News Context Stryker introduced several orthopaedic innovations at the AAOS 2026 Annual Meeting in New Orleans, headlined by Triathlon Gold, the company’s first commercially available femoral component using 3D printing with a titanium nitride surface designed for patients with metal sensitivity concerns. The company also debuted the Triathlon Medial Stabilized Insert, which provides enhanced stability while allowing natural rotational movement. On the robotics front, Stryker announced full market release of the Mako Shoulder platform, integrating robotics with Tornier Perform implants and Blueprint... Orthopaedics Innovation Surgical Robotics Medical Devices Knee Replacement Stryker https://healthcarenews.work/news/2026-03-02-stryker-honored-with-hircs-first-ever-enterprise-gold-resiliency-badge/ https://healthcarenews.work/news/2026-03-02-stryker-honored-with-hircs-first-ever-enterprise-gold-resiliency-badge/ Mon, 02 Mar 2026 00:00:00 +0000 Healthcare News Context The Healthcare Industry Resiliency Collaborative has awarded Stryker the Enterprise Gold Resiliency Badge, recognizing exceptional adaptability in healthcare supply chain performance. This is the first time the enterprise-level distinction has been awarded, building on prior recognitions for Stryker’s individual business groups: the Orthopaedic Group received the HIRC Gold Resiliency Badge in 2024, and the MedSurg and Neurotechnology Group earned the same honor in 2026. The badge assessment evaluates demand planning, inventory management, supply chain visibility, supplier management, risk management, and... Awards Supply Chain Operational Excellence Healthcare Stryker https://healthcarenews.work/news/2026-03-02-rilzabrutinib-orphan-drug-japan-igg4-related-disease/ https://healthcarenews.work/news/2026-03-02-rilzabrutinib-orphan-drug-japan-igg4-related-disease/ Mon, 02 Mar 2026 00:00:00 +0000 Healthcare News Context Japan’s Ministry of Health, Labour and Welfare has granted orphan drug designation to Sanofi’s rilzabrutinib for treating IgG4-related disease, marking the third global orphan drug designation for the oral reversible Bruton’s tyrosine kinase inhibitor. The designation was supported by positive Phase 2 study results showing that treatment over 52 weeks reduced disease flares and disease markers while minimizing glucocorticoid requirements. Common adverse events in the study included diarrhea, COVID-19, dizziness, dry mouth, and nausea, with no new safety concerns identified.... Regulatory Designation Rare Disease Immunology Japan Sanofi https://healthcarenews.work/news/2026-02-27-dupixent-chmp-positive-opinion-csu-young-children/ https://healthcarenews.work/news/2026-02-27-dupixent-chmp-positive-opinion-csu-young-children/ Fri, 27 Feb 2026 00:00:00 +0000 Healthcare News Context The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending Dupixent (dupilumab) for treating chronic spontaneous urticaria in children aged 2 to 11 years who have not responded adequately to standard antihistamine treatment. If approved, Dupixent would become the first targeted medicine in the EU indicated for this young patient population. The recommendation is supported by the LIBERTY-CUPID clinical study program, including the CUPIDKids Phase 3 study. Dupixent is a monoclonal antibody developed... Regulatory Recommendation Immunology Pediatrics CHMP Sanofi https://healthcarenews.work/news/2026-02-27-acoziborole-chmp-positive-opinion-sleeping-sickness/ https://healthcarenews.work/news/2026-02-27-acoziborole-chmp-positive-opinion-sleeping-sickness/ Fri, 27 Feb 2026 00:00:00 +0000 Healthcare News Context The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to acoziborole (Acoziborole Winthrop) as a single-dose oral treatment for both early and advanced-stage gambiense sleeping sickness. The three-tablet regimen represents a major advancement over existing therapies that require 10-day courses or injection combinations, with success rates reaching up to 96% across disease stages in Phase 2/3 trials. Sanofi has committed to donating the medicine through World Health Organization channels at no cost to... Regulatory Recommendation Neglected Tropical Diseases Public Health CHMP Sanofi https://healthcarenews.work/news/2026-02-25-uhg-authorizes-payment-quarterly-dividend/ https://healthcarenews.work/news/2026-02-25-uhg-authorizes-payment-quarterly-dividend/ Wed, 25 Feb 2026 00:00:00 +0000 Healthcare News Context The UnitedHealth Group board of directors has authorized a cash dividend of $2.21 per share, payable on March 17, 2026, to shareholders of record as of March 9, 2026. The dividend continues the company’s regular quarterly payout to shareholders. UnitedHealth Group operates as a healthcare and well-being company through two complementary divisions: Optum, which delivers technology-enabled care solutions, and UnitedHealthcare, which provides comprehensive health benefits and coverage options. The company trades on the NYSE under the ticker UNH. Investor Relations Dividend Financial UnitedHealth Group https://healthcarenews.work/news/2026-02-24-dupixent-approved-us-allergic-fungal-rhinosinusitis/ https://healthcarenews.work/news/2026-02-24-dupixent-approved-us-allergic-fungal-rhinosinusitis/ Tue, 24 Feb 2026 00:00:00 +0000 Healthcare News Context The FDA has granted priority review approval to Dupixent (dupilumab), developed by Sanofi and Regeneron, for treating adults and pediatric patients aged 6 and older with allergic fungal rhinosinusitis who have prior sinus surgery history. The approval makes Dupixent the first and only medicine specifically approved for this chronic fungal-triggered inflammatory condition of the sinuses. Results from the Phase 3 LIBERTY-AFRS-AIMS study of 62 patients showed significant improvements across key measures at week 52: a 50% improvement in sinus opacification... Regulatory Approval Immunology Respiratory FDA Sanofi https://healthcarenews.work/news/2026-02-17-filing-2025-form-20f-annual-financial-report/ https://healthcarenews.work/news/2026-02-17-filing-2025-form-20f-annual-financial-report/ Tue, 17 Feb 2026 00:00:00 +0000 Healthcare News Context Sanofi has filed its Form 20-F with the U.S. Securities and Exchange Commission and its Document d’Enregistrement Universel containing its Annual Financial Report with the French market regulator Autorite des marches financiers. The filings cover the company’s 2025 fiscal year. Both documents are accessible through the Sanofi investor relations website, the SEC website, and the AMF website. Hard copies containing complete audited financial statements are available upon request. Sanofi is listed on EURONEXT under the ticker SAN and on NASDAQ... Financial Reporting Regulatory Filing Investor Relations SEC Sanofi https://healthcarenews.work/news/2026-02-17-duvakitug-phase2b-maintenance-ulcerative-colitis-crohns/ https://healthcarenews.work/news/2026-02-17-duvakitug-phase2b-maintenance-ulcerative-colitis-crohns/ Tue, 17 Feb 2026 00:00:00 +0000 Healthcare News Context The RELIEVE UCCD long-term extension study has shown that duvakitug, a human monoclonal antibody targeting TL1A developed by Sanofi and Teva Pharmaceutical Industries, maintained robust efficacy over 44 weeks in patients with ulcerative colitis and Crohn’s disease who initially responded during induction therapy. In ulcerative colitis, clinical remission was achieved by 58% of patients on the 900 mg dose and 47% on the 450 mg dose at week 44. For Crohn’s disease, endoscopic response rates reached 55% and 41% for... Clinical Trial Results Immunology Gastroenterology Phase 2 Sanofi https://healthcarenews.work/news/2026-02-16-beyfortus-lancet-rsv-second-season-benefit/ https://healthcarenews.work/news/2026-02-16-beyfortus-lancet-rsv-second-season-benefit/ Mon, 16 Feb 2026 00:00:00 +0000 Healthcare News Context A study published in The Lancet Infectious Diseases has found that Sanofi’s Beyfortus (nirsevimab) provides significant protection against RSV hospitalizations not only during the first season but also into the second RSV season for immunized infants. The NIRSE-GAL study reported an 85.9% reduction in RSV-related lower respiratory tract infection hospitalizations during the first season and a 55.3% reduction during the second season among previously immunized infants. The universal immunization program achieved a 94.4% coverage rate, with 11,796 of 12,492 eligible... Vaccines Pediatrics RSV Clinical Evidence Publication Sanofi https://healthcarenews.work/news/2026-02-12-belen-garijo-appointed-chief-executive-officer/ https://healthcarenews.work/news/2026-02-12-belen-garijo-appointed-chief-executive-officer/ Thu, 12 Feb 2026 00:00:00 +0000 Healthcare News Context Sanofi’s Board of Directors has appointed Belen Garijo as the company’s new Chief Executive Officer, effective at the conclusion of the Annual General Meeting on April 29, 2026. Outgoing CEO Paul Hudson’s tenure ended February 17, with Olivier Charmeil serving as Interim CEO during the transition period. Garijo previously led Merck KGaA as the first female CEO of a DAX40 company and spent 15 years at Sanofi in pharmaceutical operations roles, including leading the company through the Genzyme acquisition. She... Corporate Governance Leadership CEO Appointment Sanofi https://healthcarenews.work/news/2026-02-10-sanofi-completes-acquisition-dynavax/ https://healthcarenews.work/news/2026-02-10-sanofi-completes-acquisition-dynavax/ Tue, 10 Feb 2026 00:00:00 +0000 Healthcare News Context Sanofi has completed its acquisition of Dynavax Technologies Corporation, adding the hepatitis B vaccine HEPLISAV-B and a pipeline of vaccine assets to its portfolio. The deal also includes a shingles vaccine candidate (Z-1018) currently in Phase 1/2 studies, along with additional vaccine pipeline assets. The tender offer expired on February 9, 2026, with all conditions satisfied. Non-tendered shareholders received $15.50 per share in cash through a subsequent Delaware merger that made Dynavax an indirect Sanofi subsidiary. Dynavax ceased trading on... Acquisition Vaccines Corporate Development Sanofi https://healthcarenews.work/news/2026-02-09-rilzabrutinib-breakthrough-therapy-warm-autoimmune-hemolytic-anemia/ https://healthcarenews.work/news/2026-02-09-rilzabrutinib-breakthrough-therapy-warm-autoimmune-hemolytic-anemia/ Mon, 09 Feb 2026 00:00:00 +0000 Healthcare News Context The FDA has granted breakthrough therapy designation to Sanofi’s Wayrilz (rilzabrutinib) for warm autoimmune hemolytic anemia, making it the first and only investigational BTK inhibitor for this indication to receive the designation. Simultaneously, Japan’s Ministry of Health, Labour and Welfare granted orphan drug designation for the same condition. Rilzabrutinib is an oral, reversible Bruton’s tyrosine kinase inhibitor that addresses immune-system dysregulation through multi-immune modulation. It is already approved in the U.S., EU, and UAE for immune thrombocytopenia. Warm autoimmune hemolytic... Regulatory Designation Rare Disease Hematology FDA Japan Sanofi https://healthcarenews.work/news/2026-01-27-uhg-reports-2025-results-and-issues-2026-outlook/ https://healthcarenews.work/news/2026-01-27-uhg-reports-2025-results-and-issues-2026-outlook/ Tue, 27 Jan 2026 00:00:00 +0000 Healthcare News Context UnitedHealth Group reported full-year 2025 consolidated revenues of $447.6 billion, representing 12% year-over-year growth, alongside earnings from operations of $19.0 billion and a net margin of 2.7%. Cash flows from operations reached $19.7 billion, or 1.5 times net income, with earnings per share of $13.23 and adjusted earnings per share of $16.35. For 2026, the company issued guidance including revenue greater than $439.0 billion, earnings from operations exceeding $24.0 billion, and adjusted earnings per share above $17.75. CEO Stephen Hemsley... Investor Relations Earnings Financial Results Annual Results UnitedHealth Group https://healthcarenews.work/news/2026-01-22-uhg-provides-testimony-for-house-energy-commerce-ways-means-committee-hearings/ https://healthcarenews.work/news/2026-01-22-uhg-provides-testimony-for-house-energy-commerce-ways-means-committee-hearings/ Thu, 22 Jan 2026 00:00:00 +0000 Healthcare News Context UnitedHealth Group Chairman and CEO Stephen J. Hemsley testified before the House Energy and Commerce and Ways and Means Committees regarding healthcare affordability and accessibility solutions. The company highlighted systemic cost challenges, noting that hospital prices have increased nearly three times faster than inflation over the past 25 years and represent over 30% of annual healthcare spending, while prescription drug costs have risen 269% since 2000. UnitedHealth Group said it negotiated nearly $300 billion in discounts for customers last year... Policy Healthcare Affordability Government Affairs Access UnitedHealth Group https://healthcarenews.work/news/2026-01-14-accelerated-medicare-advantage-payments/ https://healthcarenews.work/news/2026-01-14-accelerated-medicare-advantage-payments/ Wed, 14 Jan 2026 00:00:00 +0000 Healthcare News Context UnitedHealthcare has launched a Rural Payment Acceleration Pilot to assist independent rural hospitals experiencing financial strain. The six-month initiative reduces Medicare Advantage payment timelines by 50%, accelerating collections from under 30 days to under 15 days on average. Bobby Hunter, CEO of UnitedHealthcare Government Programs, said that “rural hospitals are the backbone of their communities” and that speeding up payments helps providers “focus on what matters most: patient care.” The pilot targets specific independent rural hospitals chosen through criteria designed... Medicare Advantage Rural Health Health Benefits Affordability Provider Relations UnitedHealth Group https://healthcarenews.work/news/2026-01-12-new-independent-studies-medicare-advantage-delivers-greater-value-to-federal-government-and-beneficiaries/ https://healthcarenews.work/news/2026-01-12-new-independent-studies-medicare-advantage-delivers-greater-value-to-federal-government-and-beneficiaries/ Mon, 12 Jan 2026 00:00:00 +0000 Healthcare News Context Two independent actuarial studies conducted by Milliman and released by UnitedHealth Group found that Medicare Advantage costs the federal government 9% less than traditional Medicare. Federal payments to MA plans average $1,117 per member monthly versus $1,234 for traditional Medicare, representing savings of over $1,400 annually per beneficiary. The studies also estimated that MA plans deliver $63 billion in additional annual value through supplemental benefits including dental, vision, and hearing coverage. Non-dual eligible aged-in MA beneficiaries spend 53% less on... Medicare Advantage Health Benefits Research Policy UnitedHealth Group